Cartesian Therapeutics, Inc. (RNAC) vs Zentalis Pharmaceuticals, Inc. (ZNTL)
A side-by-side comparison of Cartesian Therapeutics, Inc. and Zentalis Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RNAC
Cartesian Therapeutics, Inc.
$6.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ZNTL
Zentalis Pharmaceuticals, Inc.
$2.67HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — RNAC vs ZNTL
growth of $100 · dividends reinvested · last 7yRNAC -87.5% (-25.7%/yr)ZNTL -88.0% (-26.1%/yr)RNAC compounded faster over this window
RNAC ZNTL
RNAC vs ZNTL: by the numbers
- •RNAC is the larger company ($198M vs $190M market cap).
- •Both run net losses; ZNTL's is the smaller (0.00% vs -10422.48% net margin).
Metrics side by side
Valuation
| Metric | RNAC | ZNTL |
|---|---|---|
| P/S ratio | 134.28 | N/A |
| P/B ratio | N/A | 1.32 |
Profitability
| Metric | RNAC | ZNTL |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -3099.93% | 0.00% |
| Net margin | -10422.48% | 0.00% |
| ROE | N/A | -121.76% |
| ROIC | -33.10% | -105.17% |
Growth (annualized)
| Metric | RNAC | ZNTL |
|---|---|---|
| Revenue CAGR (5Y) | -50.01% | N/A |
| Total return CAGR (5Y) | -44.03% | -47.34% |
Frequently asked
- How have RNAC and ZNTL total returns compared?
- Over the past 5 years, RNAC delivered -44.03% and ZNTL delivered -47.34% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.